Search

Abstract Background The recently used pan-immune-inflammation value (PIV) has not been adequately studied as a predictive marker for mortality in immunosuppressed patients. The aim of this study was to evaluate the usefulness of baseline PIV level as a predictor of 30-day mortality in solid organ transplant (SOT) recipients with gram negative bloodstream infections (GN-BSI). Methods This retrospective, cross-sectional study was conducted between January 1, 2019, and December 31, 2022, in 1104 SOT recipients. During the study period, 118 GN-BSI were recorded in 113 patients. Clinical, epidemiological, and laboratory data were collected, and mortality rates (30-day and all-cause) were recorded. Results The 113 recipients had a median age of 50 years [interquartile range (IQR) 37.5–61.5 years] with a male predominance (n = 72, 63.7%). The three most common microorganisms were as follows: 46 isolates (38.9%) of Escherichia coli, 41 (34.7%) of Klebsiella pneumoniae, and 12 (10.2%) of Acinetobacter baumannii. In 44.9% and 35.6% of the isolates, production of extended-spectrum beta-lactamases and carbapenem resistance were detected, respectively. The incidence of carbapenem-resistant GN-BSI was higher in liver recipients than in renal recipients (n = 27, 69.2% vs n = 13, 17.6%, p

In solid organ transplant (SOT) recipients, invasive fungal infections (IFIs) are a significant cause of morbidity and mortality. Thus, the diagnosis, treatment, and management of these infections are of great importance. Eleven different IFIs (five candidemia, three aspergillosis, one cryptococcosis, one intra-abdominal mucormycosis, and one Magnusiomyces infection) were followed up in nine SOT recipients (four kidney, four liver, and one heart transplant), aged 35-66 years. The diagnosis of mucormycosis was based on pathology test results; the other fungi were identified via culture. One patient with candidemia (Candida parapsilosis) developed resistance to fluconazole while under treatment. The study patients had several risk factors for IFIs, including prolonged hospitalization, immunosuppression, broad-spectrum antibiotic use, renal replacement therapy, in-situ central venous catheter, previous antifungal exposure, and reoperation. Focal control was attempted in all patients by withdrawing the catheter if present. Treatments were administered based on antifungal susceptibility results, if available, or in accordance with guideline recommendations. During the follow-up period, six of the nine study patients (66.7%) died. Despite appropriate antifungal treatment and patient management, the mortality rate of IFIs remains high. Therefore, a multidisciplinary approach, including rapid diagnosis, appropriate treatment and focal control, is essential.